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Abstract
Members of the APOBEC3 family of deoxycytidine deaminases counteract a broad range of retroviruses in vitro through an
indirect mechanism that requires virion incorporation and inhibition of reverse transcription and/or hypermutation of minus
strand transcripts in the next target cell. The selective advantage to the host of this indirect restriction mechanism remains
unclear, but valuable insights may be gained by studying APOBEC3 function in vivo. Apobec3 was previously shown to
encode Rfv3, a classical resistance gene that controls the recovery of mice from pathogenic Friend retrovirus (FV) infection
by promoting a more potent neutralizing antibody (NAb) response. The underlying mechanism does not involve a direct
effect of Apobec3 on B cell function. Here we show that while Apobec3 decreased titers of infectious virus during acute FV
infection, plasma viral RNA loads were maintained, indicating substantial release of noninfectious particles in vivo. The lack
of plasma virion infectivity was associated with a significant post-entry block during early reverse transcription rather than
G-to-A hypermutation. The Apobec3-dependent NAb response correlated with IgG binding titers against native, but not
detergent-lysed virions. These findings indicate that innate Apobec3 restriction promotes NAb responses by maintaining
high concentrations of virions with native B cell epitopes, but in the context of low virion infectivity. Finally, Apobec3
restriction was found to be saturable in vivo, since increasing FV inoculum doses resulted in decreased Apobec3 inhibition.
By analogy, maximizing the release of noninfectious particles by modulating APOBEC3 expression may improve humoral
immunity against pathogenic human retroviral infections.
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Introduction
Millions of years of co-evolution of retroviruses and mammalian
hosts has led to the emergence of retroviral host restriction factors,
some of which were discovered following major efforts to
understand key steps in the HIV life cycle. Most of these genes,
such as TRIM5a [1], Tetherin/Bst2 [2] and SAMHD1 [3], restrict
retroviruses in the infected cell. In contrast, members of the
APOBEC3 family of deoxycytidine deaminases are distinguished by
their ability to inhibit retroviruses in the next target cell. In cell
culture, co-transfection of APOBEC3 expression plasmids with
retrovirus molecular clones does not decrease virus output, but the
infectivity of the resulting virions is dramatically decreased [4–5].
These APOBEC3-containing virions are fusion-competent, but
encounter post-entry blocks from early reverse transcription to
integration [6–7], with G-to-A hypermutation of nascent reverse
transcripts observed in most, but not all [8–11] retrovirus infections.
Notably, while in vivo studies have largely focused on G-to-A
hypermutation as a read-out of APOBEC3 function [12–14], the
biological relevance of APOBEC3-mediated reduction of virion
infectivity remains unclear. In fact, it is currently unknown whether
high viral output with reduced infectivity can be detected in vivo,
since multiple rounds of replication with Apobec3 restriction will
ultimately result in decreased total virus titers [15–16].
Investigating the impact of APOBEC3 restriction in vivo is
logistically difficult in humans due to potential redundancy in
antiretroviral activities of seven human APOBEC3 members
(APOBEC3A, B, C, D, F, G and H) (reviewed in [17]). Moreover,
APOBEC3 activity is likely most relevant immediately following
viral transmission, but such biological samples are very difficult to
obtain from pathogenic human retrovirus infections. In contrast,
mice encode a single Apobec3 gene (mA3) [4–5] that could be
genetically disrupted. While mA3-deficient mice are physiologically
normal [18], they proved more susceptible to pathogenic murine
retroviral infections that include Mouse Mammary Tumor virus
[8], Moloney Murine Leukemia Virus [19] and Friend retrovirus
(FV) complex [20–21]. These studies provide a springboard for
investigating the immunological impact of mA3 restriction in vivo.
FV causes severe splenomegaly and erythroleukemia in adult
immunocompetent mice, and resistance and susceptibility to FV
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have been mapped to a variety of genes [22–23]. One of these
genes, Recovery from Friend retrovirus gene 3 (Rfv3), influences the
recovery of mice from viremia by promoting a more potent
neutralizing antibody (NAb) response [24–25]. C57BL/6 (B6)
mice recover from viremia, develop stronger NAb responses and
are Rfv3 resistant, while BALB/c, A.BY and A/WySn strains
have persistent viremia, develop weaker NAb responses and are
Rfv3 susceptible. Our group and others demonstrated that the
B6 mA3 gene acts as the classical Rfv3 resistance gene,
promoting stronger NAb responses and facilitating recovery
from FV viremia, infection, and disease in (B66BALB/c)F1,
(B66A.BY)F1 and (B66A/WySn)F1 mice [20,26–27]. In
addition, the B6 mA3 gene restricted acute FV replication in
immune compartments [20–21,27–28]. Acute FV inhibition was
associated with significantly higher mA3 mRNA expression and
splicing differences in Rfv3 resistant (B6) compared to Rfv3
susceptible strains (BALB/c, A.BY, A/WySn) [10,21,26,29].
However, the mechanism through which B6 mA3 promotes FV-
specific NAb responses remains unknown.
The APOBEC3 genes are evolutionarily related to Activation-
Induced Deaminase, a B-cell specific enzyme that is critical for
antibody affinity maturation and class-switching [30]. Thus, the
identification of mA3 as Rfv3 led to the immediate hypothesis that
mA3 may directly influence antibody development [20]. However,
hapten immunization studies revealed that B6 mA3 influenced
antibody affinity maturation only in the context of FV infection
[28]. Thus, the underlying mechanism for the mA3/Rfv3
phenotype does not involve a direct effect of mA3 on B cell
function. In fact, decreased immune dysfunction was found to be a
critical component of how B6 mA3 promotes NAb responses [27–
28]. We therefore hypothesized that mA3 influences NAb
responses by promoting the release of noninfectious virions in vivo
[28], driving NAb responses without eliciting pathology.
The mechanism for the mA3/Rfv3 phenotype may have
implications for improving humoral immunity against human
retroviruses, particularly against HIV-1. However, HIV-1 encodes
Vif, which promotes the degradation of the human homologues
APOBEC3G (hA3G) and APOBEC3F (hA3F) [31–34]. Surpris-
ingly, despite the action of Vif, hA3G/hA3F-mediated G-to-A
hypermutation was detected in HIV-1 sequences from clinical
specimens [12–14]. These findings could in part be due to the
emergence of defective Vif alleles [35]. However, high hA3G
mRNA levels in primary cells or tissues were also associated with
lower HIV-1 viral loads [36–37]. In rhesus macaques infected with
SIV, rhesus macaque A3G (rhA3G) levels in colonic biopsies
following mucosal vaccination also correlated with set-point
plasma viral loads [38]. Thus, hA3G/hA3F may be induced to
levels that saturate endogenous levels of Vif. This is consistent with
in vitro observations that show inhibition of wild-type HIV-1 with
increasing hA3G transfection levels [4–5]. Unfortunately, obtaining
direct evidence that innate hA3G/hA3F restriction is saturable in
humans is not feasible.
We therefore evaluated the in vivo antiviral activity and
saturability of B6 mA3 in the context of FV infection of mice.
The results provide long-sought insights into a fundamental
APOBEC3 restriction phenotype that may have important
implications for HIV-1 vaccine research.
Results
B6 mA3 promotes substantial release of noninfectious
retroviral particles in vivo
(B66BALB/c)F1 mice (genotype Rfv3
r/s) are highly susceptible
to FV infection but recover from plasma viremia by 28 days post-
infection (dpi) due to the dominant, B6-encoded Rfv3 resistance
gene [20,26] (Figure S1A in Text S1). In contrast, the majority of
(B6 mA32/26BALB/c)F1 mice (genotype Rfv3
2/s) do not survive
to 28 dpi, and those that survive display elevated plasma viremia,
consistent with identity between Rfv3 and mA3 [20,26] (Figure S1B
in Text S1). We previously reported that the significant survival
disadvantage of (B6 mA32/26BALB/c)F1 mice was linked to
higher plasma viremia during acute infection (7 dpi), quantified on
susceptible Mus dunni cells using an FV envelope-specific
monoclonal antibody to detect foci of infectivity [39]. Thus, the
Mus dunni assay measures infectious viremia. In contrast, a
quantitative RT-PCR assay measuring total viral RNA copies
(specifically, the F-MuLV helper virus component, as described in
Materials and Methods) does not distinguish between infectious
and noninfectious virions [26,40]. To determine if B6 mA3 affected
the relative amount of infectious virions released in vivo, we
measured the ratio of virus titers obtained from both assays in
plasma from (B66BALB/c)F1 mice infected with 140 SFFU of FV
(Figure 1).
Interestingly, plasma samples from (B6 mA3+/+6BALB/c)F1
mice that had 10-fold lower infectious viremia titers at 7 dpi
compared to (B6 mA32/26BALB/c)F1 mice (Figure 1A) had
equivalent total viral RNA loads (Figure 1B). Thus, the fraction of
infectious viral particles was significantly higher in mice without a
functional B6 mA3 gene (Figure 1C). By setting the mean virion
infectivity of (B6 mA32/26BALB/c)F1 mice to 100%, the relative
infectivity of plasma virions from (B6 mA3+/+6BALB/c)F1 mice
averaged only 22% (Figure 1D). Thus, B6 mA3 restriction resulted
in approximately 5-fold higher levels of noninfectious virions at
7 dpi. Higher proportions of noninfectious particles were also
observed in (B6 mA3+/+6A.BY)F1 versus (B6 mA3
2/26A.BY)F1
mice (Figure S2 in Text S1).
Minimal mA3-associated G-to-A substitutions in viral RNA
and reverse transcripts from plasma virions isolated
during acute infection
In the absence of HIV-1 Vif, hA3G and hA3F mediate high
levels of G-to-A hypermutation in the minus strand of viral DNA,
disrupting open reading frames and effectively inactivating HIV-1.
In contrast, mA3 did not appear to induce G-to-A hypermutation
Author Summary
Members of the APOBEC3 gene family can potently inhibit
a broad range of retroviruses, including HIV-1. In cell
culture, APOBEC3 counteracts retroviruses by: (1) reducing
the infectivity of virions; and (2) inducing lethal G-to-A
hypermutation in the next target cell. The selective
advantage to the host of an ‘indirect’ restriction factor
that is incorporated into virions and acts in the next target
cell remains mysterious. We previously showed that
Apobec3 encodes Rfv3, a classical resistance gene that
controls the neutralizing antibody response against Friend
retrovirus infection in mice. Here we demonstrate that
Apobec3 promotes the release of substantial levels of
noninfectious virions in the plasma during acute FV
infection, resulting in a more potent antibody response
directed against intact virions. Thus, we propose that
APOBEC3 evolved as an innate mechanism to promote
high concentrations of retrovirus antigen in a native but
noninfectious form to effectively prime the neutralizing
antibody response. These findings could have important
implications for improving HIV-1 specific antibody re-
sponses.
Apobec3 Restricted Acute Plasma Virions
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against FV, MMTV and MLV [8–11], but these data were
obtained either from cells infected in vitro or from bulk infected
tissues. To investigate the mechanism of B6 mA3 restriction of
plasma virions released during acute infection in vivo, we
monitored FV sequence evolution in plasma from infected
(B6 mA3+/+6BALB/c)F1 and (B6 mA3
2/26BALB/c)F1 mice
(Figure 2A). Partial env sequences amplified from the FV inoculum
stock phylogenetically clustered with each other (Fig. 2B, left panel),
supporting their authenticity as reference sequences. Mutations
that were already present in the inoculum quasispecies (Figure 2B,
right panel) were then excluded from FV mutational analyses in
infected mice.
Multiple FV env sequences were obtained from 7 dpi plasma of
(B6 mA3+/+6BALB/c)F1 and (B6 mA3
2/26BALB/c)F1 mice.
Relative to the FV inoculum sequences, the cumulative mutational
load (Figure 2C), G-to-A substitutions (Figure 2C), and the
continuity of the envelope open reading frames (Figure S3 in Text
S1) in plasma viral RNA from (B6 mA3+/+6BALB/c)F1 and (B6
mA32/26BALB/c)F1 mice did not significantly differ from each
other. Thus, the reduction in the infectivity of 7 dpi plasma virions
from (B6 mA3+/+6BALB/c)F1 mice (Figure 1C) was likely not due
to disproportionately mutated viral genomes.
Newly formed FV reverse transcripts in target cells following
infection with plasma virions were next evaluated using
Figure 1. B6 mA3 promotes noninfectious particle release during acute FV infection. (B66BALB/c)F1 mice were infected with 140 SFFU of
FV complex and 7 dpi plasma samples from B6 mA3+ and B6 mA32 F1 mice were subjected to infectious viremia titration in Mus dunni cells and viral
RNA copy determinations by quantitative PCR. Virion infectivity for each sample was measured by taking the ratio of infectious titer and viral load. (A)
Infectious viremia and (B) plasma viral load during acute infection of (B66BALB/c)F1 mice are shown as log10 values. (C) Virion infectivity was
calculated by taking the ratio of log10 infectious titer and plasma viral load. (D) Virion infectivity was also compared with non-log transformed values,
setting the average infectious titer per viral copy number of (B6 mA32/26BALB/c)F1 as 100%. Samples below the assay limit of detection (below the
dotted lines in panel A) were excluded in this calculation. Solid lines correspond to mean values, and p values from a two-tailed Student’s t test are
shown. Each dot corresponds to an infected mouse. Error bars correspond to the standard error of the mean.
doi:10.1371/journal.ppat.1002284.g001
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approaches to bias for detection of G-to-A mutations [11,41–
42]. When compared to FV sequences from the inoculum and
the corresponding 7 dpi plasma samples, similar mutation
frequencies and total G-to-A substitutions were observed in
(B6 mA3+/+6BALB/c)F1 and (B6 mA3
2/26BALB/c)F1 mice
(Figure 2D). However, when these G-to-A substitutions were
partitioned into mA3-associated dinucleotide preferences, the
(B6 mA3+/+6BALB/c)F1 strain was associated with the detection
of GGRAG and GARAA mutations (Figure 2D). Thus, we
could detect signatures of mA3-associated G-to-A mutations
from reverse transcripts generated from acute B6 mA3+ plasma
virions. However, even with techniques that significantly biased
for the detection of such reverse transcripts, the G-to-A
substitution frequency obtained for FV (0.14%) was at least
10-fold lower than that observed for HIV-1 DVif, which ranges
from 1.3 to 6.5% [14]. Together, these findings suggest that
mA3-mediated deamination plays a very minor role in
restricting FV infection in vivo.
Figure 2. Mechanism of B6 mA3 inhibition of plasma virion infectivity. (A) General strategy to investigate FV evolution in vivo. FV env
sequences from the inoculum stock, 7 dpi plasma, and reverse transcripts following infection of target Mus dunni cells with 7 dpi plasma were
compared with each other. (B) Sequence characterization of the FV inoculum quasispecies. (Left) Contemporary FV sequences (gray circles) cluster in
phylogenetic analyses with .80% bootstrap value (asterisk), and diverge from a 1983 sequence, FB29. (Right) Sequence alignment against the
consensus showed 13 variant sites (vertical bars). These variations were excluded from subsequent analyses of FV mutation rates in infected mice. The
two most divergent FV sequences differed by 0.6% in nucleotide identity. (C) Virion RNA mutational loads from (B66BALB/c)F1 mice (140 SFFU) 7 dpi
plasma were compared against the FV inoculum consensus. No significant difference in mutation rates was observed (Chi-Square test). (D) Reverse
transcripts following infection of Mus dunni cells with plasma virions were amplified using conditions to bias for G-to-A mutational detection.
Substitution rates were tabulated from a combined consensus sequence derived from the FV inoculum (panel B) and the corresponding plasma
virions (panel C). mA3-associated G-to-A substitutions is associated with (B6 mA3+/+6BALB/c)F1 status by Chi-Square test. (E) mA3 inhibits FV early
reverse transcription. DNA from Mus dunni cells infected for 2 days with plasma virions were subjected to quantitative PCR for early (R-U5) and late
(R-gag) reverse transcripts, and normalized to beta-actin copy number and input virus. Differences in means were analyzed using a two-tailed
Student’s t-test.
doi:10.1371/journal.ppat.1002284.g002
Apobec3 Restricted Acute Plasma Virions
PLoS Pathogens | www.plospathogens.org 4 October 2011 | Volume 7 | Issue 10 | e1002284
Acute plasma virions from (B6 mA3+/+6BALB/c)F1 mice
are inhibited at the earliest stages of reverse
transcription
The lack of mA3-associated G-to-A substitutions in reverse
transcripts from acute plasma virions of (B6 mA3+/+6BALB/c)F1
mice argued in favor of a deamination-independent mechanism of
mA3 inhibition. Human A3G can non-enzymatically impair an
early step in HIV-1 reverse transcription involving the generation
of strong stop DNA [7,43]. Accordingly, we quantified the levels of
newly formed early (R-U5 or strong-stop DNA) and late (R-gag)
reverse transcripts following single-round infection of target cells
with 7 dpi plasma FV virions (Figure 2A). These studies revealed a
9-fold decrease in early reverse transcripts from (B6 mA3+/+6
BALB/c)F1 plasma virions compared to F1 mice lacking B6 mA3
(Figure 2E, left panel). No further decrease was observed in late
reverse transcripts (Figure 2E, right panel). Thus, the post-entry
block conferred by B6 mA3 on FV plasma virions occurred
primarily during the earliest stages of reverse transcription.
Decreased cellular FV infection levels in (B6 mA3+/+6
BALB/c)F1 mice
We previously reported that B6 mA3 decreased FV infection
levels in target cells that include erythroblasts and B cells in
(B66A.BY)F1 mice at 7 dpi [28]. FV infected cells were quantified
by flow cytometry using a Glyco-Gag specific monoclonal
antibody, MAb 34 [44]. We now extend this observation to
(B66BALB/c)F1 mice. As shown in Table 1, the percentage of
MAb 34+ cells was consistently lower in (B6 mA3+/+6BALB/c)F1
compared to (B6 mA32/26BALB/c)F1 strains in multiple cell
subpopulations in the bone marrow and the spleen. Statistical
significance was achieved with bone marrow erythroblasts and
splenic B, T and dendritic cells. These findings revealed that at
7 dpi, B6 mA3 restriction of FV virion infectivity coincided with
decreased FV infection of multiple target cells in vivo.
B6 mA3 is a saturable innate restriction factor in vivo
To test whether B6 mA3 restriction was saturable in vivo, we
infected (B6 mA3+/+6BALB/c)F1 and (B6 mA3
2/26BALB/c)F1
mice with titrated doses of FV, and measured infectious plasma
viremia at 7 dpi (Figure 3A). (B6 mA32/26BALB/c)F1 mice
exhibited significantly higher 7 dpi infectious viremia compared
to (B6 mA3+/+6BALB/c)F1 mice at all inoculum dosages, except
at the lowest dose (14 SFFU), in which most titers were below the
detection limit of the assay. The fold-difference in infectious
viremia between (B6 mA3+/+6BALB/c)F1 and (B6 mA3
2/26
BALB/c)F1 cohorts varied with the dose of the viral inoculum.
The fold-difference in B6 mA3 restriction could not be accurately
determined at 14 and 50 SFFU since several samples had
infectious titers that were below the limit of detection. Maximum
fold-difference in B6 mA3-mediated restriction was observed at
140 SFFU with 10-fold restriction (Figure 3A). At 500 SFFU and
1400 SFFU inoculum doses, there was only a 4-fold and 2-fold
effect, respectively (Figure 3A). These results demonstrate that B6
mA3-mediated restriction was saturable in vivo. Notably, even at a
higher viral dose that resulted in decreased B6 mA3 inhibition,
similar viral RNA loads (Figure 3B; left panel) and higher
noninfectious particle release (Figure 3B; right panel) were still
observed in (B6 mA3+/+6BALB/c)F1 versus (B6 mA3
2/26
BALB/c)F1 mice.
The B6 mA3-dependent NAb response correlates with
IgG titers against intact virions
The B6 mA3 gene promoted NAb responses in (B66A.BY)F1,
(B66A/WySn)F1 and pure B6 mice [20,27]. However, measure-
ments of NAb responses at 28 dpi in (B66BALB/c)F1 mice were
confounded by the increased mortality of (B6 mA32/26BALB/c)
F1 mice [20,26]. In contrast, infection with 10-fold lower dose (14
SFFU) resulted in all of the mice surviving to 28 dpi, providing an
opportunity to revisit this question in this F1 strain (Figure 4A). As
shown in Figure 4B, (B6 mA3+/+6BALB/c)F1 mice developed
significantly stronger NAb responses than (B6 mA32/26BALB/c)
F1 mice. Thus, the B6 mA3 gene promoted FV-specific NAb
responses in four genetic backgrounds that include (B66BALB/c)
F1, (B66A.BY)F1, (B66A/WySn)F1 and B6 mice.
To determine which components of the 28 dpi plasma
correlated with B6 mA3-dependent neutralization, we evaluated
the binding titers of the major immunologlobulin isotypes in
plasma, IgM and IgG. Native virions were bound to 96-well plates,
and endpoint IgM and IgG titers were determined by indirect
ELISA. Endpoint IgM titers of 28 dpi plasma from B6 mA3+ F1
and B6 mA32 F1 were not significantly different from each other
(Figure S4 in Text S1). In contrast, endpoint IgG titers against
native virions were significantly higher in (B6 mA3+/+6BALB/c)F1
compared to (B6 mA32/26BALB/c)F1 mice (Figure 4C, left panel).
Notably, this difference was not detected if detergent lysed-virions
were used (Figure 4C, right panel). Similar results were observed for
IgG endpoint titers in (B6 mA3+/+6A.BY)F1 versus (B6 mA3
2/26
A.BY)F1 mice (Figure S5 in Text S1). Thus, the B6 mA3-
dependent antibody response was distinguished by an IgG
response directed against intact virus particles.
Discussion
Mechanistic insights on the mA3/Rfv3 phenotype
The molecular identification of the classical resistance gene Rfv3
as mA3 solved a 30-year mystery in retrovirology [20,26–27].
However, this discovery unlocked new questions, foremost of
which is the mechanism for how mA3 promotes NAb responses.
Recent studies suggested an indirect mechanism that linked the
Table 1. Cellular FV infection of (B66BALB/c)F1 mice.
Cohorta
Cell subpopulationa Marker WTb KOb p-valuec
Bone marrow
Erythroid Ter119+ 19.2063.16 32.4464.48 0.0266
B cells CD19+ 20.4363.52 30.9564.32 0.0758
T cells CD3+ 23.4063.39 32.4864.56 0.1261
Dendritic cells CD11c+ 31.1364.57 41.8464.80 0.1273
Spleend
Erythroid Ter119+ 19.0662.93 24.2062.34 0.1972
B cells CD19+ 7.7360.99 10.8761.07 0.0474
T cells CD3+ 4.9260.61 6.9060.51 0.0259
Dendritic cells CD11c+ 26.8063.84 40.3963.40 0.0192
aMice were infected with 140 SFFU of FV complex and samples collected at
7 dpi. Entries correspond to mean FV+ cells 6 standard error, quantified using
a Glyco-Gag specific antibody, MAb 34.
bWT (wild-type) corresponds to (B6 mA3+/+6BALB/c)F1 mice; KO (knockout)
corresponds to (B6 mA32/26BALB/c)F1 mice. Samples sizes: WT, n = 9; KO,
n = 8.
cp-values were computed using a two-tailed Student’s t test.
dNo significant difference in spleen mass was observed (Mean:
WT= 172.2612.8 mg; KO= 200.0611.6 mg).
doi:10.1371/journal.ppat.1002284.t001
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ability of B6 mA3 to restrict FV in vivo with a more vigorous B cell
response [20–21,27–28]. However, this finding seemed counter-
intuitive in light of studies on other viral infections, particularly
HIV-1, which showed that viral antigen levels had to be preserved
to maintain virus-specific antibody levels [45–47]. FV plasma
viremia is routinely quantified using a focal infectivity assay that
measures infectious virus [20,39]. We therefore investigated whether
this method underestimated the total numbers of FV particles in
mice with functional Apobec3 activity.
Using a quantitative PCR assay for FV, B6 mA3+ F1 mice
exhibited plasma viral RNA loads that were similar to B6 mA3-
deficient F1 mice at 7 dpi. In other words, B6 mA3 activity led to
no significant change in the physical numbers of virus particles.
Instead, B6 mA3 activity reduced infectious virus titers, indicating
the release of substantial levels of noninfectious FV particles.
These B6 mA3-restricted plasma virions, which account for up to
80% of virions released during acute infection relative to B6 mA32
F1 mice, encounter a significant post-entry block in early reverse
Figure 3. B6 mA3 is a saturable innate restriction factor in vivo. (A) Saturability of innate mA3 restriction. Cohorts of (B6 mA3+/+6BALB/c)F1
and (B6 mA32/26BALB/c)F1 mice were infected with varying doses of FV and infectious viremia in 7 dpi plasma samples were measured. The fold-
difference in mean 7 dpi viremia between the wild-type and mA3-deficient F1 mice for each dose is shown. Dashed lines correspond to the limit of
detection of the focal infectivity assay (600 FFU/ml). (B) Noninfectious FV release despite decreasedmA3 restriction. Plasma viral loads (Left) and virion
infectivity (right) were determined for mice infected with 500 SFFU of FV. Plasma virion infectivity was significantly higher in (B6 mA3+/+6BALB/c)F1
compared to (B6 mA32/26BALB/c)F1 mice. A similar result was observed with a lower infection dose (140 SFFU; Figure 1C). Each dot corresponds to
an infected mouse. Differences in means were analyzed using a two-tailed Student’s t-test.
doi:10.1371/journal.ppat.1002284.g003
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transcription in the next target cell, resulting in reduced FV
infection in multiple cellular targets in vivo, including splenic B
cells. Thus, high levels of B6 mA3-restricted FV particles likely
drove the FV-specific B cell response that resulted in the
development of potent NAbs (Figure 5).
APOBEC3-restricted virions as B-cell immunogens
Native virions are potent inducers of humoral immunity.
Repeating molecular patterns on virions may be particularly
effective in cross-linking and activating B cell receptors, while viral
nucleic acids could enhance B cell responses by activating Toll-like
receptors [48]. The FV envelope glycoprotein is the primary target
of NAbs [49–50], and is organized as a trimeric spike in the native
virion, analogous to the HIV-1 envelope glycoprotein [51–52].
Detergent treatment disrupts retroviral trimers into monomeric
subunits. In this study, we show that the more potent NAb
response from B6 mA3+ F1 mice at 28 dpi correlated with
significantly higher IgG binding titers against native, but not
detergent-lysed virions. Thus, B6 mA3-restricted virions primed a
more effective IgG response directed against native envelope
trimers. Further studies are in progress to characterize the
molecular attributes of this protective NAb response.
Figure 4. NAb responses in (B66BALB/c)F1 mice. (A) Plasma samples at 28 dpi from (B6 mA3
+/+6BALB/c)F1 and (B6 mA3
2/26BALB/c)F1 mice
were heat-inactivated and analyzed for neutralization potency and virion binding. (B) B6 mA3 influences NAb responses in (B66BALB/c)F1 mice. (Left)
Neutralization curves were plotted (mean values are shown), and used to (Right) interpolate 50% inhibitory concentration (IC50) values. (C) B6 mA3
dependent NAb responses correlate with IgG antibodies directed against native virions. Endpoint ELISAs were performed on individual plasma
samples against virions that were not treated (native) or treated (detergent-lysed) with 1% Empigen-BB detergent. Values correspond to log2-
transformed reciprocal plasma dilutions that corresponded to a cut-off based on 26mean background absorbance. Each dot corresponds to an
infected mouse. Differences in means were analyzed using a two-tailed Student’s t-test.
doi:10.1371/journal.ppat.1002284.g004
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Novel insights on a fundamental APOBEC3 restriction
phenotype
APOBEC3 is unique among known virus restriction factors due
the circuitous nature of its inhibitory mechanism. Instead of simply
restricting retroviruses in the infected cell, APOBEC3 evolved the
ability to incorporate into budding virions and restrict intact
virions in the next target cell [4–5]. This biological property of
APOBEC3 is conserved from rodents (mA3) to humans (hA3G),
suggesting an important evolutionary advantage. However, despite
nearly 10 years since the discovery of this fundamental APOBEC3
phenotype [4–5], the benefits of next-round inhibition by
APOBEC3 to the host remain mysterious. Our findings suggest
that mA3 restriction functions as an innate mechanism that allow
B cell epitopes to be presented in the context of native virions,
subsequently driving the NAb response. This humoral immune
response is characterized by high specificity and memory,
attributes that could allow the host to effectively control the
infection as well as prevent subsequent infections.
Implications for HIV-1 vaccine research
Although FV and HIV-1 infect different cell types and cause
different diseases, functional similarities in APOBEC3 proteins
from mice and humans suggest that concepts developed from the
FV model may prove relevant to HIV-1 infection. Our current
model on how mA3 promotes NAb responses implicates
noninfectious virions as drivers of the Germinal Center (GC) cell
response (Figure 5). These mA3 restricted virions retain immuno-
genicity but encounter a post-entry block in target cells that
include B cells, reducing FV-induced immune dysfunction. While
HIV-1 does not infect B cells, CD4+ T cells, the primary targets of
HIV-1, also perform critical functions in the GC response, directly
interacting with B cells to promote antigen-specific antibody
development [53]. Thus, augmenting hA3G function during acute
HIV-1 infection may preserve CD4+ T cell function in GCs and
promote HIV-specific antibody development. In addition, the role
of noninfectious virions in driving the mA3/Rfv3 phenotype further
support the use of native virion mimics such as virus-like particles
or stabilized trimers as base scaffolds for vaccine design [54–55],
with the caveat that more sophisticated approaches are needed to
elicit NAbs that could broadly neutralize HIV-1 strains from
multiple subtypes.
The existence of a lentiviral A3G antagonist, Vif, provides an
opportunity to experimentally test whether modulating A3G
function can improve the lentivirus-specific humoral immune
response. In the SIV model, mutating the Vif gene in SIV to
attenuate its function [56] may allow for rhA3G to promote non-
infectious virion release and improve humoral immunity in
infected rhesus macaques. Similar studies on HIV-1 infection in
humans are not possible, but therapeutic agents that block the Vif-
hA3G interaction could prove useful. Unfortunately, compounds
independently confirmed to specifically inhibit the Vif-hA3G
interaction have yet to be identified. In this study, we provide the
first evidence that innate mA3 restriction is saturable in vivo,
possibly reflecting a delicate balance between the endogenous
Figure 5. Model for mA3 action and FV-specific humoral immunity. In Rfv3 resistant mice, high endogenous levels of mA3 may overwhelm
putative FV-encoded antagonists such as Glyco-Gag, [57] resulting in functional mA3 incorporated into budding virus particles. In contrast, low levels
of mA3 in Rfv3 susceptible strains could efficiently be inactivated. In both strains, similar levels of virus particles released during acute infection could
facilitate antigen-specific B cell development. However, virions derived from Rfv3 resistant strains encounter an early post-entry reverse transcription
block in target cells. Thus, antibody affinity maturation can occur against functional envelope trimers with decreased pathology in Rfv3 resistant mice.
In contrast, fully infectious virions from Rfv3 susceptible strains could directly infect B cells (and other immune cells), resulting in immune dysfunction
and weaker development of NAbs. We hypothesize a similar scenario during acute HIV-1 infection, except that: (1) the antagonist is HIV-1 Vif, which
degrades hA3G/hA3F; and (2) the targets are CD4+ T cells, which in germinal centers are in direct contact with and provide help for antigen-specific B
cell development.
doi:10.1371/journal.ppat.1002284.g005
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levels of mA3 and a putative mA3 antagonist encoded by FV,
Glyco-Gag [57]. Thus, inducing hA3G levels to saturate, rather
than disrupt, the interaction with Vif may be a viable alternative to
promote hA3G activity (Figure 5). Notably, Interferon-alpha (IFN-
a, a cytokine that could induce APOBEC3G expression in HIV-1
target cells in vitro [58–60], improved the kinetics of HIV-1 specific
antibody development when clinically administered during acute
HIV-1 infection in vivo [61]. Further studies on the link between
IFN-a and APOBEC3 in vivo may provide critical insights on
whether the saturability of APOBEC3 restriction can be exploited
for therapy and vaccine development.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the University of Colorado Health
Sciences Center Animal Care and Use Committee [Permit
Number B-89709(10)1E]. All infections were performed under
isoflurane anaesthesia, and all efforts were made to minimize
suffering.
Mice
B6, BALB/c and A.BY mice were purchased from The Jackson
Laboratory. B6 mA3 deficient mice were derived from the XN450
cell line [20] and backcrossed for 9 generations. Experimental
groups consist primarily of (B6 mA3+/+6BALB/c)F1 versus (B6
mA32/26BALB/c)F1 mice. The rationale for an F1 transcomple-
mentation approach is explained in more detail (Figure S1 in Text
S1). Experiments were also performed in (B6 mA3+/+6A.BY)F1
versus (B6 mA32/26A.BY)F1 mice (Figures S2, S4 and S5 in Text
S1). Note that B6, BALB/c and A.BY mice have a functional B cell
Activating Factor Receptor (BAFF-R) and normal B cell maturation
phenotype, as previously described [26]. These mice are also Fv1b
and are therefore susceptible to B-tropic FV infection [62].
Description of FV inoculum stock
Mice were infected with FV complex derived from in vivo-
passaged stocks originally used to describe Rfv3 [24,63]. This B-
tropic FV stock contains: replication-competent ecotropic Friend
murine leukemia helper virus (F-MuLV); replication-defective
spleen-focus forming virus (SFFV; Lilly-Steeves strain); lactate-
dehydrogenase elevating virus (LDV). LDV is a ‘contaminant’
RNA virus that could enhance the pathogenicity of FV by delaying
adaptive immune responses [64–65]. No polytropic or mink-cell
focus-inducing viruses (MCFs) were detectable in the virus stock by
focal immunofluorescence assay with antibodies Hy7 or mAb 516,
which detect the vast majority of MCFs [66] (detection limit of 20/
ml).
FV infection
SFFV titers in the FV stock were titered in BALB/c mice and
expressed as spleen focus forming units (SFFU) per ml.
(B66BALB/c)F1 mice were infected intravenously via the retro-
orbital route with 14 to 1400 SFFU (spleen focus forming units) in
300 ml RPMI and (B66A.BY)F1 mice were infected with 1400
SFFU. All mice were .2 months old. Plasma samples were
harvested at 7 or 28 days post-infection (dpi).
Infectious viremia titration
Infectious viremia titers were determined by serially diluting
plasma into Mus dunni cells containing 4 mg/ml polybrene (Sigma;
St Louis, MO). Infected cells were detected using a monoclonal
antibody specific to F-MuLV gp70, MAb 720, as previously
described [20,39]. Briefly, F-MuLV gp70+ cells were detected
following incubation with anti-mouse IgG conjugated to horse-
radish peroxidase and an insoluble substrate, 3-amino-9-ethylcar-
bazole (Sigma). Titers were expressed as log10 focus forming units
(FFU) per ml of plasma.
Plasma viral load
Viral RNA copy numbers were quantified by real-time PCR
(qPCR) as described [26,40]. RNA from plasma (10 ml) was
extracted using the RNAeasy kit (Qiagen; Valencia, CA), and used
as template for one-step reverse transcription and PCR (Applied
Biosystems; Carlsbad, CA) using FV-specific primers (FLVsense:
59-GGACAGAAACTACCGCCCTG and FLVantisense: 59-
ACAACCTCAGACAACGAAGTAAGA) and probe (FLVprobe:
FAM-TCGCCACCCAGCAGTTTCAGCAGC-TAMRA). Copy
numbers were interpolated from an in-plate T7-transcribed RNA
standard, and expressed as log10 copy number per ml of plasma.
Sequence alignments of the F-MuLV helper virus (GenBank
Accession #Z11128), the Lilly-Steeves SFFV strain (V01552.1)
and MCFs (L. H. Evans, unpublished data) revealed that the FV
qPCR primers have low to no significant identity with SFFV or
MCFs (data not shown). Furthermore, we tested whether the FV
qPCR primers could detect any endogenous polytropic env
sequences present at one copy per mouse genome. The FV qPCR
assay consistently detects an input of 100 copies of cloned F-
MuLV DNA. If the qPCR primers cross-react with endogenous
MLV, then we should obtain a positive signal if .100 copies of
uninfected genomic DNA are added into the reaction. An input of
100 ng genomic DNA (,34,000 genomes) from uninfected B6,
A.BY and BALB/c mice into the qPCR reaction yielded no
detectable signals. In contrast, .105 copies were detected from
100 ng genomic DNA from FV infected B6 mice at 7 dpi (S. X. Li
and M. L. Santiago, unpublished). Thus, we conclude that the
qPCR assay is specific for the F-MuLV helper virus.
Sequence analysis of FV inoculum and plasma viral RNA
RNA was extracted from the FV inoculum and acute plasma
using the RNAEasy kit (Qiagen) and reverse-transcribed using the
RT2 cDNA synthesis kit (SA Biosciences; Frederick, MD). FV env
sequences (849 bp) were obtained by amplifying with primers FV.f
(ACTTATTCCAACCATACCTCT) and FV.r (TTTAGCT-
GGTGGTATTGTTGA) using the Phusion Hi-Fidelity PCR kit
(Finnzymes; Woburn, MA). Amplicons were cloned using the
TOPO cloning kit (Invitrogen; Carlsbad, CA). FV inoculum
sequences were aligned with FB29 and PVC-211 (GenBank
Z11128 and M93134) using ClustalX (http://www.clustal.org/).
Phylogenetic trees were constructed using the neighbor joining
method with 1000 subreplicates. PVC-111 was used as outgroup.
Viral RNA sequences were compared with the FV inoculum
consensus, excluding variations that were already detected in the
inoculum. To quantify mutational loads, the total, G-to-A and
mA3-associated mutational frequencies relative to the consensus
were divided by the total number of base pairs, G nucleotides and
GG/GA dinucleotides analyzed, respectively.
FV mutational analysis of newly formed reverse
transcripts in target cells
To bias the detection of G-to-A mutations, we combined four
approaches [11,41]: (1) reverse transcripts were amplified
following a single-round infection of Mus dunni cells, to enrich
for potentially defective reverse transcripts; (2) a segment of env
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closest to the primer binding site was chosen, since this region may
be present in single-stranded DNA form for longer duration and
thereby more susceptible to deamination [67]; (3) Taq polymerase
was utilized instead of Pfu polymerase, since Pfu polymerase
activity is inhibited by deoxyuridines in DNA templates; and (4) a
denaturation temperature of 88uC was used to enrich the detection
of G-to-A hypermutated reverse transcripts, which should have a
lower melting temperature. 7 dpi plasma samples (2.5 ml) from
wild-type and B6 mA32 F1 mice were inoculated into Mus dunni
cells in a 6-well plate containing 4 mg/ml polybrene. DNA was
extracted after 2 days using the DNAeasy kit (Qiagen). PCR was
performed with 10 ng DNA, 16Sweet PCR mix (SA Biosciences),
2.5 mM dNTP, 1.25 pmol env primers FV.f and FV.r. Thermo-
cycling conditions included a 95uC 15 min hot-start, followed by
30 cycles of denaturation at 88uC for 30 s, 55uC for 30 s and 72uC
for 1.5 min. Amplicons were cloned using the TOPO-TA cloning
kit (Invitrogen) and 4–8 clones were sequenced for each sample.
Consensus from the FV inoculum and the corresponding plasma
viral RNA sequences were used as reference for analysis of
nucleotide substitutions using the HYPERMUT 2.0 software
(hiv.lanl.gov).
Quantification of early and late reverse transcripts
DNA samples as described above were subjected to absolute
quantifications for early (R-U5) and late (R-gag) FV transcripts, as
well as a housekeeping gene, beta-actin, using a Taqman assay
(Applied Biosystems; Foster City, CA) in a CFX96 real-time
system (Bio-Rad; Hercules, CA). The primers and probes are listed
as follows. Early reverse transcripts: R-U5.fwd, CTCCGATA-
GACTGAGTCG, R-U5.rev, AGACCCTCCCAAGGAACA, R-
U5.probe FAM-CCCGTGTATCCAATAAATCCTCTTGC-
TAMRA. PCR cycling conditions were 95uC 10 min followed
by 40 cycles of 95uC for 15 sec and 55.7uC for 45 sec. The
expected size of PCR product is 94 bp. Late reverse transcripts: R-
U5.fwd and R-Gag.rev, TTCGACATCCTTCCAGTGGT and
R-Gag.probe, FAM-CTGCAGCATCGTTCTGTGT-TAMRA.
The PCR conditions for R-Gag were 95uC for 10 min followed by
40 cycles of 95uC for 15 sec and 61uC for 2 min 30 sec. The
expected size of the R-Gag amplicon is 670 bp. Mouse beta-actin:
Actin.fwd, GGCACCACACCTTCTACAATG, Actin.rev, GGG-
GTGTTGAAGGTCTCAAAC, and Actin.probe FAM-TGT
GGCCCCTGAGGAGCACCC-TAMRA. PCR conditions in-
cluded a hot-start for 95uC 10 min followed by 40 cycles of
95uC for 15 sec and 60uC for 50 sec. Absolute copy numbers were
interpolated from a best-fit standard curve against a DNA
standard.
Flow cytometry
Bone marrow and spleen cells (106 cells) were stained with MAb
34, an IgG2b monoclonal antibody specific for FV Glyco-Gag
[44] for 30 min, then co-stained with: Ter119-FITC (clone TER-
119), CD3-Alexa700 (17A2), (BD Biosciences; San Diego, CA);
CD11c-PE-Cy7 (N418), (eBioscience; San Diego, CA); CD19-
PerCP-Cy5.5 (6D5) (Biolegend; San Diego, CA) and anti-mouse
IgG2b-APC (Columbia Biosciences; Columbia, MD). Isotype
controls and cells from uninfected mice were used for gating.
Cells were processed in an LSR-II flow cytometer (BD
Biosciences), collecting up to 250,000 events per sample. Datasets
were analyzed using the Flowjo software (Treestar; Ashland, OR).
Neutralizing antibody assay
Serial fourfold dilutions of heat-inactivated plasma were
incubated with F-MuLV-N stock virus in the presence of guinea
pig complement (Sigma). The antibody:virus mixture was added
into M. dunni cells and developed as in the plasma virus titrations
[20]. The number of colonies were counted and compared to a no
antibody control, which was set as 100%. Neutralization curves
were constructed, and IC50 values were calculated based on a one-
site sigmoidal fit using the Graphpad Prism software (Irvine, CA).
Virion preparation
Virion antigens were prepared from culture supernatants
obtained from Mus dunni cells infected with F-MuLV-N in T-175
flasks in the presence of 4 mg/ml polybrene (Sigma). Cellular
debris was pelleted at 18006 g for 5 min at 4uC, then the
supernatants were passed through a 0.22 mm filter. The filtered
supernatants were ultracentrifuged at 25,0006g for 2 hr at 4uC in
SW28 Ultra-Clear tubes (Beckman Coulter; Brea, CA), and virion
pellets were resuspended in 0.5 ml Tris Buffered Saline (TBS)
containing 16 protease inhibitor cocktail (Calbiochem; La Jolla,
CA) per tube and allowed to dissociate overnight at 4uC. In some
preparations, the virion pellets were resuspended in TBS with 1%
Empigen-BB (Sigma), a zwitterionic detergent that is commonly
used to solubilize viral particles and liberate envelope monomers
[68,69]. Virions were aliquoted and total protein concentrations
were determined using a BCA protein assay (Pierce; Rockford, IL).
Enzyme-linked immunosorbent assays (ELISAs)
ELISAs were performed at room temperature and 100 ml/well
volumes unless otherwise indicated. Virions (200 ng per well) were
coated into Immulon-4 HBX plates (Thermo Scientific Nunc;
Rochester, NY) overnight at 4uC and blocked with SuperBlock
(Pierce; Rockford, IL) for 2 hr. Serial 2-fold dilutions of plasma in
Phosphate Buffered Saline (PBS) were added and incubated for
1 hr. After 6 washes with PBS with 0.05% Tween-20 (PBS-T),
1:4000 biotinylated goat anti-mouse IgG (Southern Biotechnology;
Birmingham, AL) was added and incubated for 1 hr. After 6 PBS-
T washes, 1:4000 streptavidin-conjugated horseradish peroxidase
(Southern Biotechnology) was added and incubated for 30 min.
Following 6 PBS-T washes, 100 ml of TMB substrate (BioFX
Laboratories; Owings Mills, MD) was added per well and
incubated in the dark for 15 min. The reaction was stopped with
0.3N sulfuric acid (Sigma), and absorbances were read at 450 nm
in a Victor X5 plate reader (Perkin Elmer; Waltham, MA). The
same procedures were followed for the IgM ELISAs, except that
plasma samples were incubated overnight at 4uC, and 1:10000
biotinylated goat anti-mouse IgM (Southern Biotechnology) was
used. Endpoint titers were calculated by constructing one-site total
best-fit curves using the Graphpad Prism software, and interpo-
lating plasma concentrations that correspond to a cut-off value
based on twice the mean absorbance background from wells with
no plasma added. Samples from uninfected mice were also used as
negative controls, and had absorbance values below the cut-off
value (data not shown). Endpoint titers were expressed as log2
concentrations.
Statistical analyses
Differences between means were analyzed using a two-tailed
Student’s t test. The association between G-to-A mutations with
B6 mA3 status was inferred by subjecting 262 contigency tables to
a two-tailed Chi-square test. Differences with p values .0.05 were
considered not statistically significant (N.S.).
Supporting Information
Text S1 Supporting Figures S1 to S5 are presented with the
corresponding legends.
(PDF)
Apobec3 Restricted Acute Plasma Virions
PLoS Pathogens | www.plospathogens.org 10 October 2011 | Volume 7 | Issue 10 | e1002284
Acknowledgments
We thank Robert Benitez (GIVI) for technical assistance, Sam Li (UCD)
for data on FV DNA quantifications, Paul Volberding (UCSF) and Raul
Torres (UCD) for support and advice.
Author Contributions
Conceived and designed the experiments: M. Santiago, W. Greene, K.
Hasenkrug, D. Smith. Performed the experiments: D. Smith, K. Guo, B.
Barrett, K. Heilman, L. Evans, K. Hasenkrug, M. Santiago. Analyzed the
data: M. Santiago, D. Smith, K. Guo, B. Barrett, L. Evans, K. Hasenkrug.
Wrote the paper: M. Santiago, D. Smith, K. Hasenkrug, L. Evans, W.
Greene.
References
1. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, et al. (2004) The
cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old
World monkeys. Nature 427: 848–853.
2. Neil SJ, Zang T, Bieniasz PD (2008) Tetherin inhibits retrovirus release and is
antagonized by HIV-1 Vpu. Nature 451: 425–430.
3. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, et al. (2011)
SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor
counteracted by Vpx. Nature 474: 654–657.
4. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene
that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature
418: 646–650.
5. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, et al. (2003) Species-
specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114: 21–31.
6. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, et al. (2007) HIV-1
cDNAs Produced in the Presence of APOBEC3G Exhibit Defects in Plus-Strand
DNA Transfer and Integration. J Virol 81: 7099–7110.
7. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH (2008) APOBEC3G
inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4: e1000231.
8. Okeoma CM, Lovsin N, Peterlin BM, Ross SR (2007) APOBEC3 inhibits mouse
mammary tumour virus replication in vivo. Nature 445: 927–930.
9. Browne EP, Littman DR (2008) Species-specific restriction of apobec3-mediated
hypermutation. J Virol 82: 1305–1313.
10. Langlois MA, Kemmerich K, Rada C, Neuberger MS (2009) The AKV murine
leukemia virus is restricted and hypermutated by mouse APOBEC3. J Virol 83:
11550–11559.
11. Petit V, Guetard D, Renard M, Keriel A, Sitbon M, et al. (2009) Murine
APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in
vivo. J Mol Biol 385: 65–78.
12. Pace C, Keller J, Nolan D, James I, Gaudieri S, et al. (2006) Population level
analysis of human immunodeficiency virus type 1 hypermutation and its
relationship with APOBEC3G and vif genetic variation. J Virol 80: 9259–9269.
13. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, et al. (2005) GRA
hypermutation in protease and reverse transcriptase regions of human
immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol
79: 1975–1980.
14. Knoepfel SA, Di Giallonardo F, Daumer M, Thielen A, Metzner KJ (2011) In-
depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by
endogenous APOBEC3 proteins using massively parallel sequencing. J Virol
Methods 171: 329–328.
15. Hache G, Shindo K, Albin JS, Harris RS (2008) Evolution of HIV-1 isolates that
use a novel Vif-independent mechanism to resist restriction by human
APOBEC3G. Curr Biol 18: 819–824.
16. Okeoma CM, Huegel AL, Lingappa J, Feldman MD, Ross SR (2010)
APOBEC3 Proteins Expressed in Mammary Epithelial Cells Are Packaged into
Retroviruses and Can Restrict Transmission of Milk-Borne Virions. Cell Host
Microbe 8: 534–543.
17. Santiago ML, Greene WC (2008) The role of the Apobec3 family of cytidine
deaminases in innate immunity, G-to-A hypermutation and evolution of
retroviruses. In: Domingo E, Parrish CR, Holland JJ, eds. Origin and Evolution
of Viruses. London, UK: Academic Press. pp 183–206.
18. Mikl MC, Watt IN, Lu M, Reik W, Davies SL, et al. (2005) Mice deficient in
APOBEC2 and APOBEC3. Mol Cell Biol 25: 7270–7277.
19. Low A, Okeoma CM, Lovsin N, de las Heras M, Taylor TH, et al. (2009)
Enhanced replication and pathogenesis of Moloney murine leukemia virus in
mice defective in the murine APOBEC3 gene. Virology 385: 455–463.
20. Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, et al. (2008)
Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of
retrovirus infection. Science 321: 1343–1346.
21. Takeda E, Tsuji-Kawahara S, Sakamoto M, Langlois MA, Neuberger MS, et al.
(2008) Mouse APOBEC3 restricts friend leukemia virus infection and
pathogenesis in vivo. J Virol 82: 10998–11008.
22. Chesebro B, Miyazawa M, Britt WJ (1990) Host genetic control of spontaneous
and induced immunity to Friend murine retrovirus infection. Annu Rev
Immunol 8: 477–499.
23. Hasenkrug KJ, Dittmer U (2007) Immune control and prevention of chronic
Friend retrovirus infection. Front Biosci 12: 1544–1551.
24. Chesebro B, Wehrly K (1979) Identification of a non-H-2 gene (Rfv-3)
influencing recovery from viremia and leukemia induced by Friend virus
complex. Proc Natl Acad Sci U S A 76: 425–429.
25. Doig D, Chesebro B (1979) Anti-Friend virus antibody is associated with
recovery from viremia and loss of viral leukemia cell-surface antigens in leukemic
mice. Identification of Rfv-3 as a gene locus influencing antibody production.
J Exp Med 150: 10–19.
26. Santiago ML, Smith DS, Barrett BS, Montano M, Benitez RL, et al. (2011)
Persistent Friend virus replication and disease in Apobec3-deficient mice
expressing functional B-cell-activating factor receptor. J Virol 85: 189–199.
27. Tsuji-Kawahara S, Chikaishi T, Takeda E, Kato M, Kinoshita S, et al. (2010)
Persistence of viremia and production of neutralizing antibodies differentially
regulated by polymorphic APOBEC3 and BAFF-R loci in friend virus-infected
mice. J Virol 84: 6082–6095.
28. Santiago ML, Benitez RL, Montano M, Hasenkrug KJ, Greene WC (2010)
Innate retroviral restriction by Apobec3 promotes antibody affinity maturation
in vivo. J Immunol 185: 1114–1123.
29. Okeoma CM, Petersen J, Ross SR (2009) Expression of murine APOBEC3
alleles in different mouse strains and their effect on mouse mammary tumor virus
infection. J Virol 83: 3029–3038.
30. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, et al. (2000)
Class switch recombination and hypermutation require activation-induced
cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102: 553–563.
31. Stopak K, de Noronha C, Yonemoto W, Greene WC (2003) HIV-1 Vif blocks
the antiviral activity of APOBEC3G by impairing both its translation and
intracellular stability. Mol Cell 12: 591–601.
32. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme
APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med
9: 1404–1407.
33. Marin M, Rose KM, Kozak SL, Kabat D (2003) HIV-1 Vif protein binds the
editing enzyme APOBEC3G and induces its degradation. Nat Med 9:
1398–1403.
34. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, et al. (2004) Human
APOBEC3F is another host factor that blocks human immunodeficiency virus
type 1 replication. J Virol 78: 6073–6076.
35. Simon V, Zennou V, Murray D, Huang Y, Ho DD, et al. (2005) Natural
variation in Vif: differential impact on APOBEC3G/3F and a potential role in
HIV-1 diversification. PLoS Pathog 1: e6.
36. Jin X, Brooks A, Chen H, Bennett R, Reichman R, et al. (2005) APOBEC3G/
CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency
virus viremia. J Virol 79: 11513–11516.
37. Ulenga NK, Sarr AD, Thakore-Meloni S, Sankale JL, Eisen G, et al. (2008)
Relationship between human immunodeficiency type 1 infection and expression
of human APOBEC3G and APOBEC3F. J Infect Dis 198: 486–492.
38. Sui Y, Zhu Q, Gagnon S, Dzutsev A, Terabe M, et al. (2010) Innate and
adaptive immune correlates of vaccine and adjuvant-induced control of mucosal
transmission of SIV in macaques. Proc Natl Acad Sci U S A 107: 9843–9848.
39. Robertson MN, Miyazawa M, Mori S, Caughey B, Evans LH, et al. (1991)
Production of monoclonal antibodies reactive with a denatured form of the
Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity
assay, immunohistochemical studies, electron microscopy and western blotting.
J Virol Methods 34: 255–271.
40. He JY, Cheng HJ, Wang YF, Zhu YT, Li GQ (2008) Development of a real-
time quantitative reverse transcriptase PCR assay for detection of the Friend
leukemia virus load in murine plasma. J Virol Methods 147: 345–350.
41. Mahieux R, Suspene R, Delebecque F, Henry M, Schwartz O, et al. (2005)
Extensive editing of a small fraction of human T-cell leukemia virus type 1
genomes by four APOBEC3 cytidine deaminases. J Gen Virol 86: 2489–2494.
42. Suspene R, Guetard D, Henry M, Sommer P, Wain-Hobson S, et al. (2005)
Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine
deaminases in vitro and in vivo. Proc Natl Acad Sci U S A 102: 8321–8326.
43. Doitsh G, Cavrois M, Lassen KG, Zepeda O, Yang Z, et al. (2010) Abortive
HIV infection mediates CD4 T cell depletion and inflammation in human
lymphoid tissue. Cell 143: 789–801.
44. Chesebro B, Britt W, Evans L, Wehrly K, Nishio J, et al. (1983) Characterization
of monoclonal antibodies reactive with murine leukemia viruses: use in analysis
of strains of friend MCF and Friend ecotropic murine leukemia virus. Virology
127: 134–148.
45. Voltersvik P, Albrektsen G, Ulvestad E, Dyrhol-Riise AM, Sorensen B, et al.
(2003) Changes in immunoglobulin isotypes and immunoglobulin G (IgG)
subclasses during highly active antiretroviral therapy: anti-p24 IgG1 closely
parallels the biphasic decline in plasma viremia. J Acquir Immune Defic Syndr
34: 358–367.
46. Morris L, Binley JM, Clas BA, Bonhoeffer S, Astill TP, et al. (1998) HIV-1
antigen-specific and -nonspecific B cell responses are sensitive to combination
antiretroviral therapy. J Exp Med 188: 233–245.
Apobec3 Restricted Acute Plasma Virions
PLoS Pathogens | www.plospathogens.org 11 October 2011 | Volume 7 | Issue 10 | e1002284
47. Binley JM, Trkola A, Ketas T, Schiller D, Clas B, et al. (2000) The effect of
highly active antiretroviral therapy on binding and neutralizing antibody
responses to human immunodeficiency virus type 1 infection. J Infect Dis 182:
945–949.
48. Bachmann MF, Jennings GT (2010) Vaccine delivery: a matter of size,
geometry, kinetics and molecular patterns. Nat Rev Immunol 10: 787–796.
49. Messer RJ, Dittmer U, Peterson KE, Hasenkrug KJ (2004) Essential role for
virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus
infection. Proc Natl Acad Sci U S A 101: 12260–12265.
50. Britt WJ, Chesebro B (1983) Use of monoclonal anti-gp70 antibodies to mimic
the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia.
J Immunol 130: 2363–2367.
51. Yang X, Kurteva S, Ren X, Lee S, Sodroski J (2005) Stoichiometry of envelope
glycoprotein trimers in the entry of human immunodeficiency virus type 1.
J Virol 79: 12132–12147.
52. Fass D, Harrison SC, Kim PS (1996) Retrovirus envelope domain at 1.7
angstrom resolution. Nat Struct Biol 3: 465–469.
53. Reinhardt RL, Liang HE, Locksley RM (2009) Cytokine-secreting follicular T
cells shape the antibody repertoire. Nat Immunol 10: 385–393.
54. Forsell MN, Schief WR, Wyatt RT (2009) Immunogenicity of HIV-1 envelope
glycoprotein oligomers. Curr Opin HIV AIDS 4: 380–387.
55. Young KR, McBurney SP, Karkhanis LU, Ross TM (2006) Virus-like particles:
designing an effective AIDS vaccine. Methods 40: 98–117.
56. Schmitt K, Hill MS, Ruiz A, Culley N, Pinson DM, et al. (2009) Mutations in
the highly conserved SLQYLA motif of Vif in a simian-human immunodefi-
ciency virus result in a less pathogenic virus and are associated with G-to-A
mutations in the viral genome. Virology 383: 362–372.
57. Kolokithas A, Rosenke K, Malik F, Hendrick D, Swanson L, et al. (2010) The
glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral
function of APOBEC3. J Virol 84: 10933–10936.
58. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, et al. (2009)
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell
subsets. J Virol 83: 9474–9485.
59. Chen K, Huang J, Zhang C, Huang S, Nunnari G, et al. (2006) Alpha interferon
potently enhances the anti-human immunodeficiency virus type 1 activity of
APOBEC3G in resting primary CD4 T cells. J Virol 80: 7645–7657.
60. Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM (2006) Induction of
APOBEC3 family proteins, a defensive maneuver underlying interferon-induced
anti-HIV-1 activity. J Exp Med 203: 41–46.
61. Adalid-Peralta L, Godot V, Colin C, Krzysiek R, Tran T, et al. (2008)
Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients
with acute HIV-1 infection. J Leukoc Biol 83: 1060–1067.
62. Best S, Le Tissier P, Towers G, Stoye JP (1996) Positional cloning of the mouse
retrovirus restriction gene Fv1. Nature 382: 826–829.
63. Lilly F, Steeves RA (1973) B-tropic Friend virus: a host-range pseudotype of
spleen focus-forming virus (SFFV). Virology 55: 363–370.
64. Robertson SJ, Ammann CG, Messer RJ, Carmody AB, Myers L, et al. (2008)
Suppression of acute anti-friend virus CD8+ T-cell responses by coinfection with
lactate dehydrogenase-elevating virus. J Virol 82: 408–418.
65. Marques R, Antunes I, Eksmond U, Stoye J, Hasenkrug K, et al. (2008) B
lymphocyte activation by coinfection prevents immune control of friend virus
infection. J Immunol 181: 3432–3440.
66. Lavignon M, Walker JL, Perryman SM, Malik FG, Khan AS, et al. (1994)
Characterization of epitopes defining two major subclasses of polytropic murine
leukemia viruses (MuLVs) which are differentially expressed in mice infected
with different ecotropic MuLVs. J Virol 68: 5194–5203.
67. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, et al. (2004) Single-strand
specificity of APOBEC3G accounts for minus-strand deamination of the HIV
genome. Nat Struct Mol Biol 11: 435–442.
68. Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, et al. (2002)
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein
complex of human immunodeficiency virus type 1. J Virol 76: 8875–8889.
69. Pantophlet R, Wang M, Aguilar-Sino RO, Burton DR (2009) The human
immunodeficiency virus type 1 envelope spike of primary viruses can suppress
antibody access to variable regions. J Virol 83: 1649–1659.
Apobec3 Restricted Acute Plasma Virions
PLoS Pathogens | www.plospathogens.org 12 October 2011 | Volume 7 | Issue 10 | e1002284
